Cingulate Ownership

CING Stock  USD 5.73  0.07  1.24%   
The market capitalization of Cingulate is $24.03 Million. Almost 94.39 percent of Cingulate outstanding shares are held by general public with 2.39 (percent) owned by insiders and only 3.22 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
2020-03-31
Previous Quarter
3.4 M
Current Value
3.6 M
Avarage Shares Outstanding
1.8 M
Quarterly Volatility
899.3 K
 
Covid
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.

Cingulate Stock Ownership Analysis

The book value of the company was currently reported as 1.55. The company recorded a loss per share of 4.41. Cingulate had not issued any dividends in recent years. The entity had 1:12 split on the 9th of August 2024. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficithyperactivity disorder. The company was founded in 2012 and is headquartered in Kansas City, Kansas. Cingulate operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. For more info on Cingulate please contact Shane PharmD at 913 942 2300 or go to https://www.cingulate.com.

Cingulate Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cingulate is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cingulate backward and forwards among themselves. Cingulate's institutional investor refers to the entity that pools money to purchase Cingulate's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Citigroup Inc2025-03-31
0.0
Headlands Technologies Llc2024-12-31
0.0
Commonwealth Equity Services Inc2025-03-31
55.5 K
Geode Capital Management, Llc2025-03-31
30.4 K
Ubs Group Ag2025-03-31
22.1 K
Vanguard Group Inc2025-03-31
10.8 K
Alphamark Advisors, Llc2024-12-31
K
Bank Of America Corp2025-03-31
K
Tower Research Capital Llc2025-03-31
433
Sbi Securities Co Ltd2025-03-31
362
Advisor Group Holdings, Inc.2025-03-31
42.0
Note, although Cingulate's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cingulate Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cingulate insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cingulate's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cingulate insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Cingulate Outstanding Bonds

Cingulate issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cingulate uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cingulate bonds can be classified according to their maturity, which is the date when Cingulate has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Cingulate Corporate Filings

F3
10th of July 2025
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
ViewVerify
F4
9th of July 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
11th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
28th of April 2025
Other Reports
ViewVerify

Currently Active Assets on Macroaxis

When determining whether Cingulate is a strong investment it is important to analyze Cingulate's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cingulate's future performance. For an informed investment choice regarding Cingulate Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cingulate. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cingulate. If investors know Cingulate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cingulate listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.41)
Return On Assets
(1.14)
Return On Equity
(3.58)
The market value of Cingulate is measured differently than its book value, which is the value of Cingulate that is recorded on the company's balance sheet. Investors also form their own opinion of Cingulate's value that differs from its market value or its book value, called intrinsic value, which is Cingulate's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cingulate's market value can be influenced by many factors that don't directly affect Cingulate's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cingulate's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cingulate is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cingulate's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.